At the ERS Congress 2026, Aptar Digital Health presented findings from a 6-month prospective study of its respiratory disease management platform, conducted at Guy’s and St Thomas’ NHS Foundation Trust in London. Ninety adults with uncontrolled moderate-to-severe asthma were included in the analysis. While continuing their inhaled controller treatment, participants used the Respi.me app and connected inhaler sensors, and their healthcare professionals monitored them via a dashboard.
Key findings included:
“Clinically meaningful” means the improvement was larger than the minimum change considered important for patients.
These preliminary findings suggest that digital self-management may complement asthma medication and support better asthma outcomes. As this was a single-arm study without a control group, the results need to be confirmed in future controlled studies.